(Photo Courtesy: www.smh.com.au)
Together with its recently announced $48 million Series C preferred stock financing, Seres Health had over $110 million of cash and investments at the end of 2014.
In connection with the investment, Nestle Health Science's CEO, Mr Greg Behar, joined the Seres board of directors.
The proceeds from these financings will fund the further development of Seres' first-in-field, lead product candidate, SER-109, for preventing the recurrence of Clostridium difficile infection, into Phase 3 clinical trials as well as the advancement of the company's pipeline of therapeutics to treat other diseases of the human microbiome.
Seres is developing the first Ecobiotic therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome.
Current product candidates span infectious, metabolic, and inflammatory diseases.